title: Dental implant placement with bone augmentation in a patient who received intravenous bisphosphonate treatment for osteoporosis.
abstract: Intravenous (IV) administration of bisphosphonates has been considered an absolute contraindication for placement of dental implants, because of the increased risk of bisphosphonate-related osteonecrosis of the jaw (BRONJ). However, the evidence regarding this association originates from patients being treated for various forms of metastatic cancer. In the case reported here, a patient received a dental implant while undergoing IV treatment with zoledronic acid for osteoporosis. The authors discuss the current evidence regarding the risks of dental procedures in patients receiving IV bisphosphonates for this indication. They also evaluate important risk factors and the decision-making pathway in such cases. On the basis of existing evidence, receipt of a single IV infusion of zoledronic acid for the treatment of osteoporosis does not appear to be an absolute contraindication to implant placement.
authors.affiliation: The University of Hong Kong, Oral Rehabilitation, Faculty of Dentistry, HKU, Block A, 4/F, Prince Philip Dental Hospital, 34 Hospital Road, Hong Kong. nikos@mattheos.net
authors.forename: Nikos
authors.initials: N
authors.lastname: Mattheos
authors.forename: Patrick
authors.initials: P
authors.lastname: Caldwell
authors.forename: Eugen B
authors.initials: EB
authors.lastname: Petcu
authors.forename: Saso
authors.initials: S
authors.lastname: Ivanovski
authors.forename: Peter
authors.initials: P
authors.lastname: Reher
mesh_terms: D000540:Alveolar Ridge Augmentation; D059266:Bisphosphonate-Associated Osteonecrosis of the Jaw; D050071:Bone Density Conservation Agents / Q000008:administration & dosage*; D000075202:Contraindications; D003663:Decision Trees; D000044:Dental Abutments; D003758:Dental Implantation, Endosseous / Q000379:methods; D004164:Diphosphonates / Q000008:administration & dosage*; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage*; D007180:Incisor; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000188:drug therapy*; D018570:Risk Assessment; D015040:Zirconium; D000077211:Zoledronic Acid
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid; D015040:Zirconium; C028541:zirconium oxide